Ed the particle morphologies and aerosolization properties. We also observed substantial effects that physical mixing of spray-dried microparticles with coarse carrier can have around the aerosol performance. Among unique DPI formulations, powders spray dried from water-ethanol solution of your drug, DPPC and L-leucine which have been also physically blended with coarse lactose exhibited the ideal aerosolization properties. Despite obtaining noticeable burst release through the first hour of the study, some SS-containing SLmPs showed substantial release retardation compared the pure drug. The present study suggests that DPPC and L-leucine may be intriguing additives for further developments of SS inhalable powder formulationspeting interests The authors declare that they have no competing interests. Authors’ contributions ZD: Carried out the preparation and characterization with the DPI formulations and drafted the manuscript. KM: Supervisor andparticipated in drafting the manuscript. ARN: Supervisor. HRF: participated in analysis with the drug. MAB: participated in characterization from the powders. All authors study and authorized the final manuscript. Acknowledgements This study was funded and supported by Tehran University ofMedical Sciences (TUMS); grant no. 87-03-33-7715. Author particulars 1 Aerosol Analysis Laboratory, Division of Pharmaceutics, College of Pharmacy, Tehran University of Health-related Sciences, Tehran, Iran. 2Medicinal Plants Research Center, Tehran University of Medical Sciences, Tehran, Iran. 3 XRD Investigation Laboratory, College of Sciences, Tehran University, Tehran, Iran. Received: 20 February 2014 Accepted: 30 May possibly 2014 Published: 11 June 2014 References 1. Courrier H, Butz N, Vandamme TF: Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug Carrier Syst 2002, 19:no. four o. five. 2. Groneberg D, Witt C, Wagner U, Chung K, Fischer A: Fundamentals of pulmonary drug delivery. Resp Med 2003, 97:382?87. three. Labiris N, Dolovich M: Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized drugs. Brit J Clin Pharmacol 2003, 56:588?99. four. Zeng XM, Martin GP, Marriott C: The controlled delivery of drugs for the lung. Int J Pharm 1995, 124:149?64. 5. Hardy JG, Chadwick TS: Sustained release drug delivery towards the lungs. Clin Pharmacokin 2000, 39:1?. six. Cook RO, Pannu RK, Kellaway IW: Novel sustained release microspheres for pulmonary drug delivery. J Manage Rel 2005, 104:79?0. 7. Schreier H, Gonzalez-Rothi RJ, Stecenko AA: Pulmonary delivery of liposomes. J Control Rel 1993, 24:209?23.Price of Boc-amido-PEG9-amine eight.2-(Tributylstannyl)thiophene Data Sheet Lu D, Hickey AJ: Liposomal dry powders as aerosols for pulmonary delivery of proteins.PMID:23983589 AAPS PharmSciTech 2005, six:E641 648. 9. Abra R, Mihalko PJ, Schreier H: The effect of lipid composition upon the encapsulation and in vitro leakage of metaproterenol sulfate from 0.two m diameter, extruded, multilamellar liposomes. J Manage Rel 1990, 14:71?eight.10. Parthasarathy R, Gilbert B, Mehta K: Aerosol delivery of liposomal all-transretinoic acid for the lungs. Cancer Chemother Pharmacol 1999, 43:277?83. 11. Pilcer G, Amighi K: Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010, 392:1?9. 12. Taylor KM, Fan SJ: Liposomes for drug delivery for the respiratory tract. Drug Dev Ind Pharm 1993, 19:123?42. 13. Kellaway IW, Farr SJ: Liposomes as drug delivery systems towards the lung. Adv Drug Deliv Rev 1990, five:149?61. 14. Niven RW, Schreier H: Nebulization of liposomes. I. Effec.